Abstract：
BACKGROUND: In retrospective studies investigating the difference in survival by gender, there are conflicting results. It was aimed to compare overall survival (OS) and breast cancer-specific survival (BCSS) in male and female breast cancer subtypes according to the prognostic staging system.
METHODS: Overall survival rates and BCSS rates of patients diagnosed with breast cancer between 2010 and 2019 compared by gender for all cohorts, stages, and molecular subtypes using the SEER Database. The stage has been rearranged according to the eighth edition of the AJCC.
RESULTS: 364 039 patients were included in the study. .7% (n = 2503) of all breast cancers were male breast cancer. Overall survival (male: 5-year OS 73.9%, female = 5-year OS 86%) and BCSS rates (male: 5-year BCSS 78.9%, female = 5-year BCSS 94.7%) were significantly higher in females than in males for all cohorts. OS (male: 5-year OS 66.2% vs female: 5-year OS 88.3%), and BCSS (male: 5-year BCSS 88.4% vs female: 5-year 93.6%) rates were higher in hormone receptor (HR)-positive/Her2-negative female patients. Overall survival rate is higher in females in stage I (male: 5-year OS 81.5%, female: 5-year OS 92.8%), and BCSS rate is higher in stage I (male: 5-year BCSS 94.8%, female: 5-year BCSS 97.5%). Males have 2 times (HR = 2.023) higher overall mortality risk than females, but the risk of dying from breast cancer is only 1.6 times (HR = 1.596) higher.
CONCLUSIONS: Breast cancer-specific mortality is significantly higher in male breast cancers, especially in the early stage, and HR-positive subtype than females.
METHODS: Overall survival rates and BCSS rates of patients diagnosed with breast cancer between 2010 and 2019 compared by gender for all cohorts, stages, and molecular subtypes using the SEER Database. The stage has been rearranged according to the eighth edition of the AJCC.
RESULTS: 364 039 patients were included in the study. .7% (n = 2503) of all breast cancers were male breast cancer. Overall survival (male: 5-year OS 73.9%, female = 5-year OS 86%) and BCSS rates (male: 5-year BCSS 78.9%, female = 5-year BCSS 94.7%) were significantly higher in females than in males for all cohorts. OS (male: 5-year OS 66.2% vs female: 5-year OS 88.3%), and BCSS (male: 5-year BCSS 88.4% vs female: 5-year 93.6%) rates were higher in hormone receptor (HR)-positive/Her2-negative female patients. Overall survival rate is higher in females in stage I (male: 5-year OS 81.5%, female: 5-year OS 92.8%), and BCSS rate is higher in stage I (male: 5-year BCSS 94.8%, female: 5-year BCSS 97.5%). Males have 2 times (HR = 2.023) higher overall mortality risk than females, but the risk of dying from breast cancer is only 1.6 times (HR = 1.596) higher.
CONCLUSIONS: Breast cancer-specific mortality is significantly higher in male breast cancers, especially in the early stage, and HR-positive subtype than females.
摘要：
背景：在按性别调查生存率差异的回顾性研究中，有相互矛盾的结果。目的是根据预后分期系统比较男性和女性乳腺癌亚型的总体生存率（OS）和乳腺癌特异性生存率（BCSS）。
方法：2010年至2019年期间诊断为乳腺癌的患者的总体生存率和BCSS率，按性别比较所有队列，阶段,和使用SEER数据库的分子亚型。舞台已根据AJCC的第八版进行了重新安排。
结果：364.039名患者被纳入研究。所有乳腺癌中有7％（n=2503）是男性乳腺癌。总生存率（男性：5年OS73.9%，女性=5年OS86%)和BCSS比率(男性：5年BCSS78.9%，在所有队列中，女性=5年BCSS94.7％）的女性明显高于男性。OS（男性：5年OS66.2%，女性：5年OS88.3%），激素受体（HR）阳性/Her2阴性女性患者的BCSS（男性：5年BCSS88.4％vs女性：5年93.6％）发生率更高。I期女性的总生存率较高（男性：5年OS81.5%，女性：5年OS92.8%），第一阶段的BCSS比率更高(男性：5年BCSS94.8%，女性：5年BCSS97.5%）。男性的总死亡率风险是女性的2倍（HR=2.023），但是死于乳腺癌的风险只有1.6倍（HR=1.596）。
结论：男性乳腺癌的乳腺癌特异性死亡率明显较高，尤其是在早期阶段，HR阳性亚型高于女性。
方法：2010年至2019年期间诊断为乳腺癌的患者的总体生存率和BCSS率，按性别比较所有队列，阶段,和使用SEER数据库的分子亚型。舞台已根据AJCC的第八版进行了重新安排。
结果：364.039名患者被纳入研究。所有乳腺癌中有7％（n=2503）是男性乳腺癌。总生存率（男性：5年OS73.9%，女性=5年OS86%)和BCSS比率(男性：5年BCSS78.9%，在所有队列中，女性=5年BCSS94.7％）的女性明显高于男性。OS（男性：5年OS66.2%，女性：5年OS88.3%），激素受体（HR）阳性/Her2阴性女性患者的BCSS（男性：5年BCSS88.4％vs女性：5年93.6％）发生率更高。I期女性的总生存率较高（男性：5年OS81.5%，女性：5年OS92.8%），第一阶段的BCSS比率更高(男性：5年BCSS94.8%，女性：5年BCSS97.5%）。男性的总死亡率风险是女性的2倍（HR=2.023），但是死于乳腺癌的风险只有1.6倍（HR=1.596）。
结论：男性乳腺癌的乳腺癌特异性死亡率明显较高，尤其是在早期阶段，HR阳性亚型高于女性。
